Biopharma M&A stays robust as companies shift focus from megadeals to smaller targets

The article notes that despite a slowdown in large megadeals, overall merger and acquisition activity in the biopharma sector remains strong.

Companies are adopting multi‑pronged strategies to address an upcoming wave of major patent expirations, targeting smaller acquisitions that can bolster their pipelines.

Analysts point out the absence of new megadeals as a notable gap and suggest that such large transactions may not reappear in the near term.